Bionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGM

Core Insights - Bionano Genomics has announced a study that presents a new method for analyzing multiple myeloma (MM) using optical genome mapping (OGM), which addresses challenges in traditional cytogenetic analysis [1][3] - The study indicates that the new OGM method can reduce the required number of CD138-positive cells for analysis by half, making it easier to analyze limited samples [1][7] - OGM has shown a 93% concordance rate with the traditional FISH method while uncovering over 22 additional genetic variants not detected by FISH, enhancing the understanding of MM [7] Company Overview - Bionano Genomics specializes in genome analysis solutions aimed at transforming genomic research through OGM technology, diagnostic services, and software [4] - The company provides OGM solutions applicable across various research fields, including basic, translational, and clinical research [4] - Bionano also offers a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis technology [4] Industry Context - Multiple myeloma is a significant focus for researchers looking to implement OGM in routine clinical use, highlighting a substantial unmet medical need in the field of hematologic malignancies [3] - The publication of the study is seen as a pivotal advancement for OGM research in the context of blood cancers, potentially expanding the application of OGM in clinical settings [3][8]